These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25395834)

  • 1. The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats.
    Song L; Yang X; Ma Y; Wu N; Liu Z
    Drug Des Devel Ther; 2014; 8():2173-9. PubMed ID: 25395834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
    Song L; Kong M; Ma Y; Ba M; Liu Z
    Brain Res; 2009 Jun; 1276():171-9. PubMed ID: 19393228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
    Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
    Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
    BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
    Lebel M; Chagniel L; Bureau G; Cyr M
    Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
    Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
    J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Tomiyama M; Kimura T; Maeda T; Kannari K; Matsunaga M; Baba M
    Neurosci Res; 2005 Jun; 52(2):185-94. PubMed ID: 15893579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
    Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
    Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
    Zhang X; Andren PE; Chergui K; Svenningsson P
    Neuropharmacology; 2008 Jun; 54(7):1143-52. PubMed ID: 18423776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.